Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Metab Pharmacokinet. 2008;23(2):87-94.

Intestinal first-pass metabolism of CYP3A4 substrates.

Author information

1
Pre-clinical Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan. katomth@chugai-pharm.co.jp

Abstract

Cytochrome P450 3A4 (CYP3A4) is present not only in the liver but also in the small intestine, where it functions as a barrier against xenobiotics. Some CYP3A4 substrates exhibit low bioavailability due to intestinal first pass metabolism. The AUCs of such CYP3A4 substrates are remarkably changed by the inhibition, induction, and saturation of CYP3A4 and so prediction of intestinal first-pass metabolism is important. In this article, factors affecting intestinal first-pass metabolism of drugs are reviewed, focusing on the intestinal metabolism by CYP3A. The methods to predict intestinal first-pass metabolism are also reviewed.

PMID:
18445987
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
    Loading ...
    Support Center